Holen Sie sich die Stockscreener-App
93.11
0.43%
-0.40
Schlusskurs vom Vortag:
$93.51
Offen:
$93.02
24-Stunden-Volumen:
331.24K
Relative Volume:
0.80
Marktkapitalisierung:
$1.37B
Einnahmen:
$1.30M
Nettoeinkommen (Verlust:
$-140.06M
KGV:
-10.30
EPS:
-9.0441
Netto-Cashflow:
$-129.83M
1W Leistung:
+4.50%
1M Leistung:
-14.29%
6M Leistung:
+14.15%
1J Leistung:
+536.87%
1-Tages-Spanne:
$92.18
$95.99
1-Wochen-Bereich:
$87.20
$96.08
52-Wochen-Spanne:
$13.97
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
93.11 | 1.37B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy - TipRanks
FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy - Stock Titan
FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com - Investing.com Australia
FDA accepts Inhibrx Biosciences filing for ozekibart in metastatic chondrosarcoma - Traders Union
Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com - Investing.com South Africa
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma - PR Newswire
Number of shareholders of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
(INBX) Risk Channels and Responsive Allocation - Stock Traders Daily
INBX Q1 2026 Earnings: EPS Misses Estimates as Stock Gains on Operational UpdatesRetail Earnings Report - newsline.com
Inhibrx Biosciences (INBX) director receives 15,000 stock options at $95.22 strike - Stock Titan
Inhibrx Biosciences (INBX) director receives grant of 15,000 stock options - Stock Titan
Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22 - Stock Titan
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting - TipRanks
Inhibrx Biosciences (NASDAQ: INBX) investors approve directors and BDO - Stock Titan
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Stifel reiterates Inhibrx Biosciences stock rating on durability data By Investing.com - Investing.com Canada
Inhibrx Biosciences targets research advances at ASCO26 to accelerate new cancer treatments - Traders Union
INBX Q1 2026 Earnings: EPS Miss Amid Pre-Revenue R&D FocusEPS Growth Report - newsline.com
Inhibrx Biosciences (INBX) Slips 2% as Stock Tests Key Support Amid Biotech VolatilityVolatility Breakout Picks - The Legal Advocate
(INBX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Inhibrx Biosciences (INBX) Edges Higher as Stock Holds Above SupportRVOL Spike - The Legal Advocate
INBX Stock Price, Quote & Chart | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Inhibrx Biosciences (INBX) Surges Over 5% as Biotech Momentum BuildsCollar Trade - thelegaladvocate.com
How Positive INBRX-106 Phase 2 Data And Narrower Losses At Inhibrx Biosciences (INBX) Have Changed Its Investment Story - Sahm
Inhibrx Biosciences Hits Day Low of $99.70 Amid Price Pressure - MarketsMojo
Inhibrx Biosciences (INBX) price target increased by 66.67% to 255.00 - MSN
Inhibrx Inc stock (US45720L1070): trial update around ozekibart keeps biotech investors watching - AD HOC NEWS
TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation - AASTOCKS.com
Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study - MSN
Inhibrx Biosciences, Inc.Common Stock (NQ: INBX - The Chronicle-Journal
This biotech stock surges after positive cancer trial results. What to know. - MSN
Liquidity Mapping Around (INBX) Price Events - Stock Traders Daily
Inhibrx cancer treatment shows high response rates in head and neck cancer study - MSN
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Viking Global holds 1.46M shares in Inhibrx (INBX); amendment removes one reporter - Stock Titan
Perceptive (INBX) reports a 9.99% stake in INHIBRx via Schedule 13G/A - Stock Titan
Inhibrx Biosciences 1Q Loss/Shr $2.15 >INBX - Moomoo
Inhibrx Reports First Quarter 2026 Financial Results - Arizona Daily Sun
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $325 - Moomoo
Inhibrx & Invesco Mortgage Capital Q1 2026 Results - Punjab Kesari English
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer - BioPharma APAC
Inhibrx Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibrx Biosciences (INBX) cuts Q1 2026 loss, boosts cash but ups debt - Stock Titan
Inhibrx Biosciences (INBX) advances ozekibart BLA and INBRX-106 after strong oncology data - Stock Titan
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study - Insider Monkey
Inhibrx Inc stock (US45720L1070): Biotech firm in Virtus ETF holdings - AD HOC NEWS
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):